Guest Post


Visit streaming.thesource.com for more information

Different research objectives have led to incorporating Gonadorelin at different concentrations in experimental settings. This all-inclusive overview provides useful information on the subject since studies have indicated that Gonadorelin may have potential research properties such as:

– Getting testosterone production back up and running after an AAS cycle
– Intervention for advanced hypogonadism
– Relevant research data in the context of menstrual irregularities

Advertisement

Gonadorelin Peptide: What is it?

Gonadorelin, a synthetic peptide, has the same molecular blueprint and action mechanisms as the naturally occurring gonadotropin-releasing hormone (GnRH). The hypothalamus in the brain produces GnRH, which in turn instructs the pituitary gland to secrete LH and FSH, two gonadotropins meaning luteinizing hormone and follicle-stimulating hormone, respectively. There are significant functions that LH and FSH perform:

– Hormones like luteinizing hormone (LSH) and follicle-stimulating hormone (FSH) stimulate the ovaries to make estrogen and progesterone, which control fertility, ovulation, and menstruation.
– Hormones LH and FSH help with sperm more easily and increase testosterone production.

Studies suggest that Gonadorelin, similar to natural GnRH, may stimulate the pituitary gland to produce LH and FSH. 

Gonadorelin Peptide and Testosterone Synthesis

Investigations purport that when the HPG axis is inhibited, as it is during or after the presentation of anabolic-androgenic steroids (AAS) or testosterone replacement (TRT), Gonadorelin may help boost it. Several seminal works in this area are as follows:

– A concentration of Gonadorelin (GnRH) has been hypothesized to raise LH levels significantly in all groups, according to a study comprising 13 research models with an AAS exposure, 8 males, and 5 hypogonadal males. The level of luteinizing hormone (LH) reached by 5 research models with AAS exposure was theorized to be within the normal reference control group’s 5th percentile. All groups suggested a rise in LH levels, more than doubling. The control group still appeared to have the greatest hormone levels.
– A case study detailed symptoms, including testicular shrinkage, AAS exposure, abnormally low levels of luteinizing hormone and follicle-stimulating hormone, and testosterone levels of 130 ng/dl. The symptoms appeared to be controlled after Gonadorelin’s presentation, even though they lingered for months after the AAS was stopped. The study models were given Gonadorelin three times a day. Testosterone, luteinizing hormone, and free somatotropin levels were all hypothesized to be within the lower half of the reference range two hours after each concentration. In particular, at the end of the second day of the intervention, the subject’s testosterone levels appeared to have increased to 383ng/dL. Throughout the 12-month follow-up, the subject seemed to have maintained normal plasma testosterone levels.
– Research has indicated that male species may exhibit a drop in LH and testosterone levels when given higher concentrations of Gonadorelin. 7 research models were recruited in a trial that used the peptide with TRT for 11 days. The researchers saw an increase in LH and FSH at the beginning of the trial, but the Gonadorelin effect seemed to fade by the end of the first 10 to 14 days, and it continued to decline until the very end. Compared to a comparable experiment including Gonadorelin plus TRT, the research indicates that repeated presentation of Gonadorelin may result in quicker LH reduction.

Gonadorelin Peptide and Menstrual Cycle

Findings imply that conditions like functional hypothalamic amenorrhea (FHA) have been addressed with Gonadorelin using continuous pulse presentations. The hypothalamus’s decreased GnRH output causes the pituitary gland’s decreased release of LH and FSH, essential for ovulation; hence, menstrual periods stop in FHA.

The goal of ovulation induction using pulsatile GnRH is to help female research models become pregnant by stimulating the organism’s natural processes. An interesting research study with 66 research models used an implanted Gonadorelin pump that delivers the peptide every 90 minutes to induce ovulation 212 times. Some of the more interesting findings from this experiment are as follows:

– It has been hypothesized that 96% of Gonadorelin cycles were speculated to have ovulation, with 75% exhibiting mono-follicular ovulation itself. According to this, ovulation induction seemed effective for most research models.
– The study’s 65.9% live birth rate (LBR) suggested an effective approach. Per presentation, an 80.5% biochemical pregnancy rate was determined, which indicates an early pregnancy before ultrasounds can detect it.

Please note that none of the substances mentioned in this article have been approved for human consumption and should not be acquired or utilized by unlicensed individuals outside of contained research environments such as laboratories. 

References

[i] Maggi, R. (2016). Physiology of gonadotropin[1]releasing hormone (GnRH): beyond the control of reproductive functions. MOJ Anat Physiol, 2(5), 150- 154.

[ii] Quaas, P., Quaas, A. M., Fischer, M., & De Geyter, C. (2022). Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. Journal of assisted reproduction and genetics, 39(12), 2729–2736. https://doi.org/10.1007/s10815-022-02656-0

[iii] Blumenfeld Z, Makler A, Frisch L, Brandes JM. Induction of spermatogenesis and fertility in hypogonadotropic azoospermic men by intravenous pulsatile gonadotropin-releasing hormone (GnRH). Gynecol Endocrinol. 1988 Jun;2(2):151-64. doi: 10.3109/09513598809023623. PMID: 3055820.

[iv] Happ J, Ditscheid W, Krause U. Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann’s syndrome or constitutional delay of puberty. Fertil Steril. 1985 Apr;43(4):599- 608. doi: 10.1016/s0015-0282(16)48504-3. PMID: 3921412.

[v] Zhang, L., Cai, K., Wang, Y., Ji, W., Cheng, Z., Chen, G., & Liao, Z. (2019). The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. American journal of men’s health, 13(1), 1557988318818280. https://doi.org/10.1177/1557988318818280

[vi] van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med. 2003 Apr;24(3):195-6. doi: 10.1055/s[1]2003-39089. PMID: 12740738.